FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626667474> ?p ?o ?g. }

• W2626667474 endingPage "12724" @default.
• W2626667474 startingPage "12713" @default.
• W2626667474 abstract "Alzheimer disease is associated with deposition of the amyloidogenic peptide Aβ in the brain. Passive immunization using Aβ-specific antibodies has been demonstrated to reduce amyloid deposition both in vitro and in vivo. Because N-terminally truncated pyroglutamate (pE)-modified Aβ species (AβpE3) exhibit enhanced aggregation potential and propensity to form toxic oligomers, they represent particularly attractive targets for antibody therapy. Here we present three separate monoclonal antibodies that specifically recognize AβpE3 with affinities of 1–10 nm and inhibit AβpE3 fibril formation in vitro. In vivo application of one of these resulted in improved memory in AβpE3 oligomer-treated mice. Crystal structures of Fab-AβpE3 complexes revealed two distinct binding modes for the peptide. Juxtaposition of pyroglutamate pE3 and the F4 side chain (the “pEF head”) confers a pronounced bulky hydrophobic nature to the AβpE3 N terminus that might explain the enhanced aggregation properties of the modified peptide. The deep burial of the pEF head by two of the antibodies explains their high target specificity and low cross-reactivity, making them promising candidates for the development of clinical antibodies. Alzheimer disease is associated with deposition of the amyloidogenic peptide Aβ in the brain. Passive immunization using Aβ-specific antibodies has been demonstrated to reduce amyloid deposition both in vitro and in vivo. Because N-terminally truncated pyroglutamate (pE)-modified Aβ species (AβpE3) exhibit enhanced aggregation potential and propensity to form toxic oligomers, they represent particularly attractive targets for antibody therapy. Here we present three separate monoclonal antibodies that specifically recognize AβpE3 with affinities of 1–10 nm and inhibit AβpE3 fibril formation in vitro. In vivo application of one of these resulted in improved memory in AβpE3 oligomer-treated mice. Crystal structures of Fab-AβpE3 complexes revealed two distinct binding modes for the peptide. Juxtaposition of pyroglutamate pE3 and the F4 side chain (the “pEF head”) confers a pronounced bulky hydrophobic nature to the AβpE3 N terminus that might explain the enhanced aggregation properties of the modified peptide. The deep burial of the pEF head by two of the antibodies explains their high target specificity and low cross-reactivity, making them promising candidates for the development of clinical antibodies." @default.
• W2626667474 created "2017-06-23" @default.
• W2626667474 creator A5001127178 @default.
• W2626667474 creator A5003446676 @default.
• W2626667474 creator A5013946124 @default.
• W2626667474 creator A5029505811 @default.
• W2626667474 creator A5048371545 @default.
• W2626667474 creator A5061759067 @default.
• W2626667474 creator A5073976993 @default.
• W2626667474 creator A5074351885 @default.
• W2626667474 creator A5077912452 @default.
• W2626667474 creator A5078054782 @default.
• W2626667474 date "2017-07-01" @default.
• W2626667474 modified "2023-10-14" @default.
• W2626667474 title "Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy" @default.
• W2626667474 cites W1250804522 @default.
• W2626667474 cites W1514539285 @default.
• W2626667474 cites W1604272660 @default.
• W2626667474 cites W1607136952 @default.
• W2626667474 cites W1823519853 @default.
• W2626667474 cites W1927066019 @default.
• W2626667474 cites W1970983444 @default.
• W2626667474 cites W1974023102 @default.
• W2626667474 cites W1974145718 @default.
• W2626667474 cites W1974156328 @default.
• W2626667474 cites W1979818695 @default.
• W2626667474 cites W1980206150 @default.
• W2626667474 cites W1981458288 @default.
• W2626667474 cites W1985323612 @default.
• W2626667474 cites W1989972829 @default.
• W2626667474 cites W1990632702 @default.
• W2626667474 cites W1999017783 @default.
• W2626667474 cites W2006761942 @default.
• W2626667474 cites W2009733405 @default.
• W2626667474 cites W2010357514 @default.
• W2626667474 cites W2015484447 @default.
• W2626667474 cites W2015883754 @default.
• W2626667474 cites W2024917017 @default.
• W2626667474 cites W2027132952 @default.
• W2626667474 cites W2028379029 @default.
• W2626667474 cites W2029018340 @default.
• W2626667474 cites W2033373102 @default.
• W2626667474 cites W2056034415 @default.
• W2626667474 cites W2058819008 @default.
• W2626667474 cites W2060851420 @default.
• W2626667474 cites W2063808031 @default.
• W2626667474 cites W2067214887 @default.
• W2626667474 cites W2067626695 @default.
• W2626667474 cites W2071310220 @default.
• W2626667474 cites W2081855136 @default.
• W2626667474 cites W2081912151 @default.
• W2626667474 cites W2086523105 @default.
• W2626667474 cites W2097338951 @default.
• W2626667474 cites W2107363753 @default.
• W2626667474 cites W2108959691 @default.
• W2626667474 cites W2113759533 @default.
• W2626667474 cites W2124026197 @default.
• W2626667474 cites W2127154595 @default.
• W2626667474 cites W2142807222 @default.
• W2626667474 cites W2157706167 @default.
• W2626667474 cites W2163341755 @default.
• W2626667474 cites W2167867892 @default.
• W2626667474 cites W2170543101 @default.
• W2626667474 cites W2180229411 @default.
• W2626667474 cites W2199527005 @default.
• W2626667474 cites W2329336071 @default.
• W2626667474 cites W2407359553 @default.
• W2626667474 cites W2510806376 @default.
• W2626667474 cites W3014251530 @default.
• W2626667474 cites W4211213171 @default.
• W2626667474 cites W4247759744 @default.
• W2626667474 cites W4248872320 @default.
• W2626667474 doi "https://doi.org/10.1074/jbc.m117.777839" @default.
• W2626667474 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5535044" @default.
• W2626667474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28623233" @default.
• W2626667474 hasPublicationYear "2017" @default.
• W2626667474 type Work @default.
• W2626667474 sameAs 2626667474 @default.
• W2626667474 citedByCount "23" @default.
• W2626667474 countsByYear W26266674742017 @default.
• W2626667474 countsByYear W26266674742018 @default.
• W2626667474 countsByYear W26266674742019 @default.
• W2626667474 countsByYear W26266674742020 @default.
• W2626667474 countsByYear W26266674742021 @default.
• W2626667474 countsByYear W26266674742022 @default.
• W2626667474 crossrefType "journal-article" @default.
• W2626667474 hasAuthorship W2626667474A5001127178 @default.
• W2626667474 hasAuthorship W2626667474A5003446676 @default.
• W2626667474 hasAuthorship W2626667474A5013946124 @default.
• W2626667474 hasAuthorship W2626667474A5029505811 @default.
• W2626667474 hasAuthorship W2626667474A5048371545 @default.
• W2626667474 hasAuthorship W2626667474A5061759067 @default.
• W2626667474 hasAuthorship W2626667474A5073976993 @default.
• W2626667474 hasAuthorship W2626667474A5074351885 @default.
• W2626667474 hasAuthorship W2626667474A5077912452 @default.
• W2626667474 hasAuthorship W2626667474A5078054782 @default.
• W2626667474 hasBestOaLocation W26266674741 @default.
• W2626667474 hasConcept C12554922 @default.

• next